Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ADHD [NASD]
Alcobra Ltd.
Index- P/E- EPS (ttm)-1.87 Insider Own- Shs Outstand13.64M Perf Week5.12%
Market Cap238.02M Forward P/E- EPS next Y-1.99 Insider Trans- Shs Float7.32M Perf Month-17.18%
Income-24.40M PEG- EPS next Q-0.56 Inst Own31.20% Short Float10.11% Perf Quarter-11.56%
Sales- P/S- EPS this Y-420.00% Inst Trans3.55% Short Ratio4.45 Perf Half Y-15.29%
Book/sh2.59 P/B6.74 EPS next Y8.70% ROA-62.60% Target Price33.63 Perf Year11.29%
Cash/sh2.85 P/C6.12 EPS next 5Y- ROE-67.40% 52W Range13.63 - 26.96 Perf YTD-3.06%
Dividend- P/FCF- EPS past 5Y0.00% ROI- 52W High-35.27% Beta-
Dividend %- Quick Ratio8.30 Sales past 5Y- Gross Margin- 52W Low28.03% ATR1.00
Employees9 Current Ratio8.30 Sales Q/Q- Oper. Margin- RSI (14)44.24 Volatility5.84% 5.68%
OptionableYes Debt/Eq0.00 EPS Q/Q-280.00% Profit Margin- Rel Volume2.27 Prev Close17.96
ShortableYes LT Debt/Eq0.00 EarningsAug 11 Payout- Avg Volume166.57K Price17.45
Recom2.00 SMA20-4.16% SMA50-6.19% SMA200-7.52% Volume377,901 Change-2.84%
27-Aug-14Initiated FBR Capital Mkt Perform $23
26-Jun-14Initiated WBB Securities Hold $18
17-Apr-14Initiated Canaccord Genuity Buy $24
04-Dec-13Initiated Stifel Buy $27
08-Oct-13Reiterated Aegis Capital Buy $30 → $40
08-Jul-13Initiated Aegis Capital Buy $30
19-Sep-14 04:21PM  Alcobra Announces Completion of All Patient Visits in Phase III Clinical Trial of MDX in Adult ADHD GlobeNewswire
18-Sep-14 08:10AM  Alcobra (ADHD) Worth Watching: Stock Moves 5.1% Higher Zacks
05-Sep-14 08:00AM  Alcobra Ltd. to Present at the Aegis Healthcare & Technology Conference GlobeNewswire
06:41AM  Weakness Seen in Alcobra (ADHD): Stock Falls 6.6% Zacks
02-Sep-14 08:00AM  Alcobra Announces Enrollment of First Patient in Phase IIb Clinical Trial of MDX in Adolescents With ADHD GlobeNewswire
27-Aug-14 09:58AM  Why Alcobra (ADHD) Stock Is Declining Today at TheStreet
06:23AM  Coverage initiated on Alcobra Pharma by FBR Capital Briefing.com
20-Aug-14 05:21PM  Alcobra Starts Patient Enrollment for Mid-Stage Study on MDX Zacks
19-Aug-14 08:00AM  Alcobra Announces Enrollment of First Patient in Phase IIb Clinical Trial of MDX in Fragile X Syndrome GlobeNewswire
11-Aug-14 08:30AM  Alcobra Ltd Earnings Call scheduled for 8:30 am ET today CCBN
08:15AM  Alcobra Ltd Earnings Call scheduled for 8:30 am ET today CCBN
07:36AM  Alcobra Ltd Earnings Call scheduled for 8:30 am ET today CCBN
07:07AM  Q2 2014 Alcobra Ltd Earnings Release - Time Not Supplied CCBN
07:00AM  Alcobra Announces Second Quarter Financial Results and Provides Corporate Update GlobeNewswire
08-Aug-14 08:41AM  Alcobra Releases New Neuroimaging Data Supporting Pro-Cognitive Effects of MDX GlobeNewswire
06-Aug-14 08:00AM  Alcobra Ltd. to Provide Corporate Overview at the Canaccord Genuity 34th Annual Growth Conference GlobeNewswire +6.92%
01-Aug-14 08:00AM  Alcobra Ltd. to Release Second Quarter 2014 Results and Host Investor Conference Call and Webcast on Monday, August 11 GlobeNewswire
17-Jul-14 08:12AM  Alcobra Discusses New Market Research and Updates on Recent Corporate Events at Investor Forum in New York City GlobeNewswire
14-Jul-14 08:00AM  Alcobra Completes Patient Recruitment in Phase III Clinical Trial of MDX in Adult ADHD GlobeNewswire
07-Jul-14 08:00AM  Alcobra to Host Investor Forum and Webcast on July 15 in New York City GlobeNewswire
03-Jul-14 09:04AM  5 Stocks Spiking on Unusual Volume at TheStreet
08:16AM  Alcobra (ADHD) Jumps: Stock Adds 5.9% in Session Zacks
02-Jul-14 07:19AM  Alcobra shares should be bought ahead of data, says Stifel theflyonthewall.com +5.85%
26-Jun-14 09:13AM  Coverage initiated on Alcobra Pharma by WBB Securities Briefing.com
09:13AM  Coverage initiated on Alcobra Pharma by WBB Securities
24-Jun-14 06:56AM  Weakness Seen in Alcobra (ADHD): Stock Falls 6.7% Zacks
06:56AM  Weakness Seen in Alcobra (ADHD): Stock Falls 6.7%
17-Jun-14 08:00AM  Alcobra Ltd. to Provide Corporate Overview at the JMP Securities Healthcare Conference GlobeNewswire
08:00AM  Alcobra Ltd. to Provide Corporate Overview at the JMP Securities Healthcare Conference
12-Jun-14 02:25AM  Alcobra Ltd. (ADHD) Jumps: Stock Rises 8.7% Zacks
02:25AM  Alcobra Ltd. (ADHD) Jumps: Stock Rises 8.7%
09-Jun-14 08:00AM  Alcobra to Present at the American Society of Clinical Psychopharmacology Annual Meeting and the BIO International Convention GlobeNewswire
08:00AM  Alcobra to Present at the American Society of Clinical Psychopharmacology Annual Meeting and the BIO International Convention
27-May-14 08:00AM  Alcobra Ltd. to Provide Corporate Overview at the Jefferies 2014 Global Healthcare Conference GlobeNewswire
08:00AM  Alcobra Ltd. to Provide Corporate Overview at the Jefferies 2014 Global Healthcare Conference
23-May-14 08:00AM  Alcobra Ltd. to Present at the Gordon Research Conference on Fragile X and Autism-Related Disorders GlobeNewswire
08:00AM  Alcobra Ltd. to Present at the Gordon Research Conference on Fragile X and Autism-Related Disorders
15-May-14 01:33PM  Alcobra's (ADHD) CEO Yaron Daniely on Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
01:33PM  Alcobra's (ADHD) CEO Yaron Daniely on Q1 2014 Results - Earnings Call Transcript
07:30AM  Alcobra Announces First Quarter Financial Results and Corporate Update GlobeNewswire
07:30AM  Alcobra Announces First Quarter Financial Results and Corporate Update
12-May-14 08:22AM  Alcobra presents improved data for Metadoxine at theflyonthewall.com
08:22AM  Alcobra presents improved data for Metadoxine
08:00AM  Alcobra Ltd. Presents Evidence of Novel Mechanism of Action for Metadoxine Extended Release (MDX) in Cognitive Disorders at the Society of Biological Psychiatry Annual Meeting GlobeNewswire
08:00AM  Alcobra Ltd. Presents Evidence of Novel Mechanism of Action for Metadoxine Extended Release (MDX) in Cognitive Disorders at the Society of Biological Psychiatry Annual Meeting
08-May-14 12:22PM  Alcobra gets FDA approval for Phase IIb trial of MDX at theflyonthewall.com
12:22PM  Alcobra gets FDA approval for Phase IIb trial of MDX
12:20PM  Alcobra Announces FDA Clearance of Protocol for Phase IIb Study of Metadoxine Extended Release (MDX) in the Treatment of Fragile X Syndrome GlobeNewswire
08:00AM  Alcobra Ltd. to Provide Corporate Overview at Oppenheimer and BioMed Conferences GlobeNewswire
07:24AM  Society of Biological Psychiatry to hold scientific meeting at theflyonthewall.com
07-May-14 04:05PM  Alcobra Ltd. to Release First Quarter 2014 Results and Host Investor Conference Call on Thursday, May 15, 2014 GlobeNewswire
06-May-14 11:52AM  Alcobra Ltd. Poised To Gain Some Attention In ADHD Market at Seeking Alpha
05-May-14 08:00AM  Alcobra Ltd. Presents Positive Results From Phase IIb Study of Metadoxine Extended Release (MDX) in Adults With Predominantly Inattentive ADHD at APA Annual Meeting GlobeNewswire
01-May-14 08:00AM  Alcobra Issued New US Patent Covering Metadoxine Use for Cognitive Disorders GlobeNewswire
24-Apr-14 08:00AM  Alcobra Ltd. to Present New Data for Metadoxine Extended Release (MDX) at Upcoming Meetings GlobeNewswire
17-Apr-14 07:58AM  Coverage initiated on Alcobra Pharma by Canaccord Genuity Briefing.com +6.08%
10-Apr-14 12:30PM  Alcobra Ltd. Submits Protocol to FDA for Phase IIb Clinical Study of Metadoxine Extended Release (MDX) in the Treatment of Fragile X Syndrome GlobeNewswire -5.21%
04-Apr-14 01:04PM  ALCOBRA LTD. Financials EDGAR Online Financials
08:31AM  Venture Capitalist Ran Nussbaum Brings Big Finance To Little Biotechs at Seeking Alpha
26-Mar-14 08:00AM  Alcobra Announces Shares Uplisted to NASDAQ Global Market GlobeNewswire
24-Mar-14 11:10AM  Pipeline Update from Alcobra Zacks
18-Mar-14 09:28AM  Todays Top Biotech Stories: Prosensa, Medivation, and Alcobra at Motley Fool
08:10AM  Alcobra announces enrollment of first patient in Phase 3 clinical trial for MDX at theflyonthewall.com
08:00AM  Alcobra Announces Enrollment of First Patient in Phase 3 Clinical Trial for MDX in Adult ADHD GlobeNewswire
07-Mar-14 05:40PM  Alcobra Gains IND Clearance for MDX Zacks
05:40PM  Alcobra Gains IND Clearance for MDX
06-Mar-14 09:18AM  Alcobra announces FDA clearance of IND for MDX at theflyonthewall.com +7.07%
09:18AM  Alcobra announces FDA clearance of IND for MDX
09:15AM  Alcobra Announces FDA Clearance of IND for Metadoxine Extended Release (MDX) GlobeNewswire
26-Feb-14 06:08AM  Alcobra (ADHD) Jumps: Stock Rises 8.5% Zacks
06:08AM  Alcobra (ADHD) Jumps: Stock Rises 8.5%
24-Feb-14 08:00AM  Alcobra Ltd. to Discuss Biomarkers in Fragile X and Autism Trials at the Second Annual Autism Investment Conference GlobeNewswire
19-Feb-14 05:19PM  CFO Moves: Alcobra, OpenX Technologies, Garmin at The Wall Street Journal
05:19PM  CFO Moves: Alcobra, OpenX Technologies, Garmin
04:29PM  CFO Moves: Alcobra, OpenX Technologies, Garmin at The Wall Street Journal
08:00AM  Alcobra Appoints J.P. Morgan Banker Dr. Tomer Berkovitz as Chief Financial Officer GlobeNewswire
17-Feb-14 12:47PM  Alcobra's CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
12:47PM  Alcobra's CEO Discusses Q4 2013 Results - Earnings Call Transcript
13-Feb-14 06:08PM  U.S./Canada daily earnings hits & misses Feb 13 - 1800 ET Reuters
05:05PM  U.S./Canada daily earnings hits & misses Feb 13 - 1700 ET Reuters
08:00AM  Alcobra Announces Fourth Quarter and Fiscal Year End 2013 Financial Results and Corporate Update GlobeNewswire
07-Feb-14 01:58PM  Alcobra Announces IND Submission for Extended Release Metadoxine to Treat Adults With ADHD GlobeNewswire +6.22%
31-Jan-14 08:00AM  Alcobra Ltd. to Provide Corporate Overview at 16th Annual BIO CEO & Investor Conference GlobeNewswire
08:00AM  Alcobra Ltd. to Provide Corporate Overview at 16th Annual BIO CEO & Investor Conference
29-Jan-14 08:00AM  Alcobra Ltd. to Release Fourth Quarter 2013 Results and Host Investor Conference Call on Thursday, February 13, 2014 GlobeNewswire
08:00AM  Alcobra Ltd. to Release Fourth Quarter 2013 Results and Host Investor Conference Call on Thursday, February 13, 2014
27-Jan-14 08:00AM  Alcobra Announces New Biomarker Finding in a Follow-Up Fragile X Animal Study for MG01CI GlobeNewswire
08:00AM  Alcobra Announces New Biomarker Finding in a Follow-Up Fragile X Animal Study for MG01CI
22-Jan-14 02:29AM  Alcobra (ADHD) Jumps: Stock Rises 9.0% Zacks
02:29AM  Alcobra (ADHD) Jumps: Stock Rises 9.0%
15-Jan-14 11:35AM  Alcobra's ADHD Program Moving To Pediatrics at Seeking Alpha
11:35AM  Alcobra's ADHD Program Moving To Pediatrics
14-Jan-14 06:12PM  Six Israeli Biotech New Issues Set A Blistering Pace at Investor's Business Daily
06:12PM  Six Israeli Biotech New Issues Set A Blistering Pace
13-Jan-14 08:00AM  Alcobra Strengthens Management Team With Addition of Industry Veteran David C. Baker as Chief Commercial Officer GlobeNewswire
08:00AM  Alcobra Strengthens Management Team With Addition of Industry Veteran David C. Baker as Chief Commercial Officer
18-Dec-13 09:50AM  FDA Grants Orphan Drug Status to Metadoxine in Fragile X Syndrome GlobeNewswire
09:50AM  FDA Grants Orphan Drug Status to Metadoxine in Fragile X Syndrome
17-Dec-13 03:04PM  Alcobra: A Speculative Biopharmaceutical Company With An Intriguing ADHD Drug Candidate at Seeking Alpha
03:04PM  Alcobra: A Speculative Biopharmaceutical Company With An Intriguing ADHD Drug Candidate
Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of proprietary drug candidates. It offers most advanced product (MDX) for the treatment of attention deficit hyperactivity disorder (ADHD) and other cognitive dysfunctions, including Fragile X. The company has initiated a Phase III clinical trial in the United States for the use of MDX to treat ADHD in adults. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel.